首页> Annals of surgery> A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103).

A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103).

导出原文传递

翻译打印收藏纠错

第一作者： Eileen M,Bulger

第一单位： University of Washington, Harborview Medical Center, Seattle, Washington.

作者： Eileen M,Bulger ^[1] ; Addison K,May ^[2] ; Bryce R H,Robinson ^[1] ; David C,Evans ^[3] ; Sharon,Henry ^[4] ; John M,Green ^[5] ; Eric,Toschlog ^[6] ; Jason L,Sperry ^[7] ; Peter,Fagenholz ^[8] ; Niels D,Martin ^[9] ; Wayne M,Dankner ^[10] ; Greg,Maislin ^[11] ; David,Wilfret ^[10] ; Andrew C,Bernard ^[12] ; ACCUTE Study Investigators

作者单位： University of Washington, Harborview Medical Center, Seattle, Washington. ^[1] Atrium Health, Charlotte, North Carolina. ^[2] Ohio Health, Grant & Mansfield Hospitals, Columbus, Ohio. ^[3] University of Maryland, Baltimore, Maryland. ^[4] Carolinas Medical Center, Charlotte, North Carolina. ^[5] East Carolina University, Greenville, North Carolina. ^[6] University of Pittsburgh, Pittsburgh, Pennsylvania. ^[7] Massachusetts General Hospital, Boston, Massachusetts. ^[8] University of Pennsylvania, Philadelphia, Pennsylvania. ^[9] Atox Bio Ltd, Durham, North Carolina. ^[10] Biomedical Statistical Consulting, Wynnewood, Pennsylvania. ^[11] University of Kentucky, Lexington, Kentucky. ^[12]